.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Moodys
Express Scripts
Harvard Business School
Novartis
McKesson
Johnson and Johnson
QuintilesIMS
Chinese Patent Office
Medtronic

Generated: December 13, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,415,342

« Back to Dashboard

Which drugs does patent 8,415,342 protect, and when does it expire?


Patent 8,415,342 protects BESIVANCE and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,415,342

Title:Besifloxacin ophthalmic composition for the treatment or control of infection
Abstract: A composition comprises besifloxacin in an amount effective for treating or controlling an infection caused by an antibiotic-resistant bacterium. Such a composition can be administered to a subject for the treatment or control of bacterial conjunctivitis caused bay an antibiotic-resistant bacterium.
Inventor(s): Tyle; Praveen (Pittsford, NY), Gupta; Pramod Kumar (Pittsford, NY), Norton; Susan E. (Rochester, NY), Brunner; Lynne (Webster, NY), Blondeau; Joseph (Saskatoon, CA)
Assignee: Bausch & Lomb Incorporated (Rochester, NY)
Application Number:12/604,422
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Bausch And LombBESIVANCEbesifloxacin hydrochlorideSUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYesYes► Subscribe► Subscribe► SubscribeMETHOD OF TREATING OCULAR BACTERIAL INFECTIONS
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,415,342

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)2010051291► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Novartis
McKinsey
Johnson and Johnson
Federal Trade Commission
Covington
Baxter
Teva
Colorcon
Medtronic
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot